title: Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
authors.affiliation: Department of Haematology, Hospital San Salvatore, Pesaro, Italy.
authors.forename: Anna
authors.initials: A
authors.lastname: Mele
authors.forename: Giovanni
authors.initials: G
authors.lastname: Sparaventi
authors.forename: Barbara
authors.initials: B
authors.lastname: Guiducci
authors.forename: Giuseppina
authors.initials: G
authors.lastname: Nicolini
authors.forename: Francesca
authors.initials: F
authors.lastname: d'Adamo
authors.forename: Giuliana
authors.initials: G
authors.lastname: Leopardi
authors.forename: Costante
authors.initials: C
authors.lastname: Delfini
authors.forename: Pierpaolo
authors.initials: P
authors.lastname: Piccaluga
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Visani
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D000922:Immunotoxins / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000922:Immunotoxins; D003561:Cytarabine; D000079982:Gemtuzumab